Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Mentice Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Mentice şirketinin toplam hissedar öz sermayesi SEK152.6M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK310.5M ve SEK157.9M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 57.14m
Eşitlik	SEK 152.59m
Toplam yükümlülükler	SEK 157.92m
Toplam varlıklar	SEK 310.51m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MN2 'nin kısa vadeli varlıkları ( SEK171.2M ) kısa vadeli yükümlülüklerini ( SEK157.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: MN2 şirketinin kısa vadeli varlıkları ( SEK171.2M ) uzun vadeli yükümlülüklerini ( SEK594.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MN2 borçsuzdur.

Borcun Azaltılması: MN2 son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Kârsız olan MN2 mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.

Tahmini Nakit Akışı: MN2 kârlı değildir ancak serbest nakit akışının pozitif olması ve yılda % 43.8 oranında büyümesi nedeniyle 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.

Mentice Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: kr0.67 (vs kr0.064 in 2Q 2023)

Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)

Mentice AB (publ) to Report Fiscal Year 2023 Final Results on Apr 24, 2024

Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)

New minor risk - Market cap size

New major risk - Share price stability

Mentice Receives FDA 510(K) Clearance for Ankyras

Mentice Receives FDA 510(K) Clearance for Ankyras

Mentice AB (publ) (OM:MNTC) agreed to acquire All substantial assets of Biomodex from SIMARATO SAS for €0.2 million.

Director recently bought €71k worth of stock

Mentice (publ) Appoints Ulrika Drotz Voksepp as New Chief Financial Officer, Effective January 2, 2024

Mentice AB (Publ) Announces Board Appointments

Third quarter 2023 earnings released

Mentice AB (publ), Annual General Meeting, May 23, 2024

Mentice AB (publ) to Report First Half, 2024 Results on Jul 23, 2024

Mentice AB (Publ) Appoints of Jonatan Sjöström to Its Executive Management Group as Chief Operating Officer, Effective from September 14, 2023

New minor risk - Market cap size

Mentice AB (publ) Announces Chief Financial Officer Changes

Second quarter 2023 earnings released: EPS: kr0.06 (vs kr0.72 loss in 2Q 2022)

Insufficient new directors

Mentice AB (publ) Announces Resignation of Gunilla Andersson as Chief Financial Officer

Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021)

Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021)

Third quarter 2022 earnings released: kr0.30 loss per share (vs kr0.29 loss in 3Q 2021)

Mentice AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

Mentice AB (publ), Annual General Meeting, May 11, 2023

Second quarter 2022 earnings released: kr0.71 loss per share (vs kr0.22 loss in 2Q 2021)

Mentice AB (publ) to Report Q4, 2022 Results on Feb 09, 2023

Mentice AB (publ) (OM:MNTC) completed the acquisition of All assets of the Ankyras software suite from Galgo Medical SL.

Mentice AB (publ) (OM:MNTC) agreed to acquire All assets of the Ankyras software suite from Galgo Medical SL for €2.775 million.

First quarter 2022 earnings released: kr0.30 loss per share (vs kr0.50 loss in 1Q 2021)

High number of new directors

Mentice AB (publ) Announces Change of Chairman of Board, Effective December 30, 2022

High number of new directors

Mentice Appoints Jan Grund Pedersen as New Vice President of Strategic Alliances & Business Development

Mentice AB (publ) to Report Fiscal Year 2021 Results on Apr 06, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: kr0.29 loss per share (vs kr0.014 loss in 3Q 2020)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Chief Financial Officer Elisabet Lund has left the company

Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020)

Less than half of directors are independent

Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.50 loss per share (vs kr0.21 loss in 1Q 2020)

New 90-day low: €7.52

Full year 2020 earnings released: kr0.54 loss per share (vs kr1.05 loss in FY 2019)

Revenue misses expectations

Mentice Announces Executive Appointments

Mentice AB (publ) to Report Fiscal Year 2020 Results on Feb 04, 2021

Third quarter 2020 earnings released: kr0.01 loss per share

Revenue misses expectations

Mentice AB (Publ) Announces Nomination Committee

New 90-day low: €7.00

Mentice AB (publ) (OM:MNTC) entered into agreement to acquire substantially all assets of EQIP, Inc. for $0.25 million.

Mentice AB (publ) (OM:MNTC) signed a definitive agreement to acquire Substantial All Assets of Vascular Simulations LLC for $6 million.

Mentice AB (publ) to Report Q2, 2020 Results on Aug 13, 2020

Mentice AB (publ) to Report Q3, 2020 Results on Nov 12, 2020

New 90-day high - €7.36

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin